# BRC Biotechnology (Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brc-biotechnology-shanghai-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Series A (Dec 29, 2025)
- Investors on record: 2

## About

Established in 2022 and based in Shanghai, China, BRC Biotechnology (Shanghai) Co., Ltd. operates as a biosecurity testing services provider that provides biosafety testing solutions and related services. The company is headquartered in Shanghai, and passed ISO9001: 2015, CMA, BSL-1 and BSL-2 compliance qualifications. It has 6000 square meters of testing service platform, business office and training center. Cergentis China and SGS Life Sciences Northeast Asia are the strategic partners of the company. In December 2025, BRC Biotechnology (Shanghai) Co., Ltd. closed over CNY 100 million in Series A funding led by new investor Cenova Ventures, with participation from new investor Dalton Venture.

The company focuses on developing testing service platform which provides biosafety testing solution services for various drug forms, such as antibody drugs, vaccine products, nucleic acid drugs, stem cell products and cellular gene therapy.

The company generates revenue from providing biosecurity testing services.

## Funding rounds

- Series A, Dec 29, 2025 — Cenova Ventures, Dalton Venture

## Investors

- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series A
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series A